strong beat/rais price
remain overweight rate share new price target yet
anoth strong oper quarter upsid contribut across portfolio
competit risk key legaci product like neulasta enbrel insignific
think organ deserv benefit doubt respect navig
coupl impress growth key newer product like repatha
parsabiv well posit commentari newli launch aimovig like
opportun continu upsid moreov despit stock solid
ytd move still trade ep in-lin group
like clockwork seem find way post non-gaap
ep well ahead consensu pjc upsid oper
driven revenu beat handili total revenu versu consensu
pjc asid enbrel saw q-q inventori drawdown almost
major product beat specif wed call attent repatha second straight
quarterli upsid post outcom data label parsabiv versu consensu
pjc key larg dialysi provid still pilot drug aimovig
revenu report yet month launch commentari appear posit
risk stori exist specif effect
migrat almost neulasta market onpro system convers seem
stall leav market vulner newli launch biosimilar
neulasta also far kept mum enbrel impact co-pay
accumul season impact tend felt patient summer month
margin worri could manifest pressur drug similar
humira presag
price close juli
ep discount back
year
rais price target amgn slow steadi perform may
sexi higher growth stori biotech think given recent volatil
name exampl investor may appreci littl slow steadi
perform chang valuat methodolog -- appli multipl
ep discount back -- price target move
higher ep estim due lower share count partial laps
global biopharmaceut compani
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
